/ Not yet recruitingPhase 1 评价注射用多西他赛脂质体在恶性实体肿瘤患者中的安全性、耐受性和药代动力学特征的I期临床研究
[Translation] A phase I clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of liposome docetaxel for injection in patients with malignant solid tumors
确定注射用多西他赛脂质体在恶性实体瘤患者中的安全性、耐受性,包括最大耐受剂量(MTD)和剂量限制性毒性(DLT)、 药代动力学特征
[Translation] To determine the safety, tolerability, including the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), and pharmacokinetic characteristics of liposome docetaxel for injection in patients with malignant solid tumors
100 Clinical Results associated with Changzhou Pacific Pharmaceutical Research Institute Co., Ltd.
0 Patents (Medical) associated with Changzhou Pacific Pharmaceutical Research Institute Co., Ltd.
100 Deals associated with Changzhou Pacific Pharmaceutical Research Institute Co., Ltd.
100 Translational Medicine associated with Changzhou Pacific Pharmaceutical Research Institute Co., Ltd.